1. Nivolumab-associated IgA Nephropathy in a Child With Malignant Melanoma.
- Author
-
Yildiz G, Torun Bayram M, Ünlü ŞM, Soylu A, Kavukçu S, and Olgun N
- Subjects
- Humans, Male, Immune Checkpoint Inhibitors adverse effects, Child, Antineoplastic Agents, Immunological adverse effects, Female, Nivolumab adverse effects, Glomerulonephritis, IGA drug therapy, Glomerulonephritis, IGA chemically induced, Glomerulonephritis, IGA pathology, Melanoma drug therapy
- Abstract
Immune checkpoint inhibitors are humanized antibodies that inhibit downregulatory receptors on T cells, enhancing the antitumor activity of these cells. However, they have been associated with a wide range of systemic immune-related adverse events, including renal toxicities, among others. Most renal immune-related adverse events are acute interstitial nephritis causing acute kidney injury. Recently, immune checkpoint inhibitors-associated glomerular diseases, including IgA nephropathy, have been reported in adults. Most of the adult cases with glomerular involvement had also concomitant acute interstitial nephritis and acute kidney injury. We present the first pediatric case of IgA nephropathy without acute kidney injury during nivolumab treatment., Competing Interests: The authors declare no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF